Behbood Sadrolhefazi

Reproductive characteristics and the risk of breast cancer--a case-control study in Iran.

Parvin Yavari, M Mosavi-Zadeh, Behbood Sadrolhefazi et al. · PubMed · 2005 · 59 citations

Medicine, Oncology, Cancer Epidemiology +13

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer

Peter Ellis, Natasha B. Leighl, Vera Hirsh et al. · Clinical Lung Cancer · 2015 · 58 citations

Medicine, Oncology, Pharmacology +10

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With <i>HER2</i> Alterations: A Phase Ia Dose-Escalation Study

John V. Heymach, Frans L. Opdam, Minal Barve et al. · Journal of Clinical Oncology · 2025 · 44 citations · Full text

Medicine, Oncology, Pharmacology +16

A descriptive retrospective study of bladder cancer at a hospital in Iran (1973-2003).

Parvin Yavari, Behbood Sadrolhefazi, Mohammad Ali Mohagheghi et al. · PubMed · 2009 · 26 citations

Medicine, Oncology, Radiation Oncology +15

An epidemiological analysis of cancer data in an Iranian hospital during the last three decades.

Parvin Yavari, Behbood Sadrolhefazi, Mohammad Ali Mohagheghi et al. · PubMed · 2009 · 22 citations

Medicine, Oncology, Radiation Oncology +16